Podium to Practice: Chicago 2026 – MELANOMA: Novel MEK/BRAF Inhibitors in BRAF-Mutant Melanoma
OR
Studies / Trials Discussed
9512 – Phase 1b study of a brain-penetrant MEK inhibitor, PF-07799544, plus next-generation BRAF dimer inhibitor, PF-07799933, in advanced BRAF-mutant melanoma.
Chair
Speakers
Explore more from your favourite experts – click their name to access their entire library of content.
Studies/trials discussed:
9512 – Phase 1b study of a brain-penetrant MEK inhibitor, PF-07799544, plus next-generation BRAF dimer inhibitor, PF-07799933, in advanced BRAF-mutant melanoma.
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.